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Background:The countries of Central and Eastern Europe have among the highest world-
wide rates of renal cell cancer (RCC). Few studies have examinedwhether genetic variation
in xenobiotic metabolic pathway genes may modify risk for this cancer. Methods: The
Central and Eastern Europe Renal Cell Cancer study was a hospital-based case–control
study conducted between 1998 and 2003 across seven centers in Central and Eastern
Europe. Detailed data were collected from 874 cases and 2053 controls on demograph-
ics, work history, and occupational exposure to chemical agents. Genes [cytochrome P-
450 family, N -acetyltransferases, NAD(P)H:quinone oxidoreductase I (NQO1), microsomal
epoxide hydrolase (mEH ), catechol-O-methyltransferase (COMT ), uridine diphosphate-
glucuronosyltransferase (UGT )] were selected for the present analysis based on their
putative role in xenobiotic metabolism. Haplotypes were calculated using fastPhase. Odds
ratios and 95% conﬁdence intervals were estimated by unconditional logistic regression
adjusted for country of residence, age, sex, smoking, alcohol intake, obesity, and hyper-
tension. Results:We observed an increased risk of RCC with one SNP. After adjustment
for multiple comparisons it did not remain signiﬁcant.NeitherNAT1 norNAT2 slow acetyla-
tion was associated with disease. Conclusion:We observed no association between this
pathway and renal cell cancer.
Keywords: renal cell cancer, epidemiology, NAT1, NAT2, CYP, NQO1, mEH, COMT
INTRODUCTION
Globally, there are 210,000 cases and 100,000 deaths each year from
kidney cancer. The countries of Central and Eastern Europe have
among the highest worldwide rates of this disease, particularly the
Czech Republic, which has an incidence of 23.6/100,000 among
men and 10.9/100,000 among women (Ferlay et al., 2010). The
majority (>90%) of adult kidney cancers are renal cell carcinomas
(RCC; Eble et al., 2004).
Established risk factors for this cancer include cigarette smok-
ing, hypertension, obesity, and von Hippel–Lindau syndrome, a
rare condition caused by alternations or deletions in the VHL
gene at chromosome 3p25. Suspected risk factors include dia-
betes mellitus and acquired cystic kidney disease (Scelo and Bren-
nan, 2007). There is additionally some evidence for an inverse
association between RCC risk and physical activity and moderate
intake of alcohol (Chow and Devesa, 2008). While not normally
considered an occupational cancer, studies have linked RCC to
occupational exposure to styrene, gasoline or other petroleum
products, asbestos, and organic solvents, particularly trichloroeth-
ylene (Mandel et al., 1995; Dosemeci et al., 1999; Bruning et al.,
2003; Charbotel et al., 2006; Heck et al., 2010).
The capacity of an individual to activate or transform envi-
ronmental toxins into less harmful intermediates, and the speed
of metabolism, is important for modifying cancer risk. Sev-
eral reviews have highlighted the genes associated with these
processes and their relationship with the development of can-
cer (Hashibe et al., 2003; Nishikawa et al., 2004). Xenobiotic
metabolizing enzymes activate (Phase I) substrates into more
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reactive metabolites (cytochrome P-450 family) or play a detox-
ifying role (Phase II), which reduces the DNA reactivity of
genotoxic species and increases excretion (N -acetyltransferases,
NAD(P)H:quinone oxidoreductase I (NQO1), microsomal epox-
ide hydrolase (mEH ), catechol-O-methyltransferase (COMT ),
uridine diphosphate-glucuronosyltransferase (UGT )). Both the
Phase I and Phase II steps in toxin metabolism are inﬂuenced
by genetic variation, affecting the rate at which carcinogens are
metabolized and eliminated.
To date, there is a scarce literature examining polymorphisms
in xenobiotic metabolizing genes in relation to RCCs. These stud-
ies found varying results, with some ﬁnding an association with
CYP1A1 (Schulz et al., 1997; Longuemaux et al., 1999; Farker
et al., 2000; Semenza et al., 2001; Sasaki et al., 2004; Tanaka et al.,
2007;Wiesenhutter et al., 2007; Smits et al., 2008). The purpose of
this study was to examine the relationship between occupational
exposures, common variation in metabolizing genes and kidney
cancer.
MATERIALS AND METHODS
STUDY PARTICIPANTS
A hospital-based case–control study was conducted between 1998
and 2003 across seven centers in Central and Eastern Europe.
The study centers were in the Czech Republic (Ceske, Prague,
Olomouc, Brno), Poland (Lodz), Romania (Bucharest), and Rus-
sia (Moscow). In each center, investigators recruited a series of
newly diagnosed cases of primary kidney cancer. Eligibility criteria
included histologically conﬁrmed disease (ICD-0-2 code C64) and
residence in the study area for at least 1 year. Cases were recruited
within 3months of diagnosis. Additional details on the study have
been reported elsewhere (Heck et al., 2010). All tumors under-
went central review to conﬁrm histology; the present analysis was
limited to RCC.
In all centers, hospital-based controls were chosen among per-
sons admitted to the same hospital as the cases with conditions
unrelated to tobacco, including benign disorders, common infec-
tions, minor surgical conditions, eye conditions (except cataract
or diabetic retinopathy), and common orthopedic diseases (except
osteoporosis). No single disease made up greater than 20% of the
control group (diseases of digestive system: 24%, musculoskeletal
system/connective tissue: 12%, genitourinary system: 11%, skin
and subcutaneous tissue: 10%, circulatory system: 9%, central ner-
vous system: 9%, eye and ear: 8%, and other smaller categories
combined: 17%). Some controls had been previously recruited
from an earlier lung cancer case–control study (Boffetta et al.,
2005). Controls were frequency matched to cases by sex, age
(±3 years), center, referral (or of residence) area, and period of
recruitment (±6months).
Across centers, participation rates ranged from 90 to 99%
among cases and 90 to 96% among controls. Written informed
consent was obtained from all subjects prior to interview. Ethical
approval was obtained from relevant review boards.
Trained interviewers administered a standardized question-
naire to participants which elicited information on personal
medical history, family history of cancer, tobacco smoking, alco-
hol drinking, dietary and anthropometric factors, other lifestyle
habits, and occupational history. The occupational interview
consisted of a general questionnaire for each job, and for
16 prespeciﬁed jobs (toolmaker or machinist, motor vehicle
mechanic, miner/quarryman, woodworker, painter, welder, insu-
lation worker, meat worker or farmer, and the steel, coke man-
ufacture, foundry, glass, tannery, chemical, and rubber indus-
tries) a speciﬁc questionnaire was also used. The general ques-
tionnaire intended to ascertain complete occupational history
and additional information relevant to exposure assessment,
including job titles, tasks, industries, starting and stopping dates,
full-time/part-time status, working environments, and speciﬁc
exposures.
The occupational exposure assessment was completed by local
experts, including chemists, industrial hygienists, and occupa-
tional physicians, who had practical experience in industrial
hygiene and took into account regional differences in use of mate-
rials, production processes, and prevention measures and changes
in exposure patterns within and across jobs and industries over
time for the different exposures. We attempted to standardize
exposure assessment through yearly workshops and coding exer-
cises. All participating study centers applied the same occupational
questionnaires and the same protocol for expert assessment. We
assessed inter-rater agreement,ﬁnding reasonably good agreement
between experts (k between 0.53 and 0.64; Mannetje et al., 2003).
Coders, blinded to case–control status, classiﬁed positions using
the International Standard Classiﬁcation of Occupation 1968 ver-
sion (ISCO-68; International LabourOfﬁce,1969)while industries
were coded according to the Statistical Classiﬁcation of Economic
Activities of the European Community, 1999 version (NACE-99;
Eurostat, 1999). Main effects results of the occupational analyses
have been reported elsewhere (Karami et al., 2008; Heck et al.,
2010; Moore et al., 2010; Boffetta et al., 2011).
Blood samples were collected and stored at −80˚C prior to
genotyping. All subjects in this study provided written informed
consent. This study was approved by ethical review boards at the
National Cancer Institute, the International Agency for Research
on Cancer, and at each participating center.
GENOTYPING
Genes were selected based on their putative role in xenobi-
otic metabolism. Genotyping took place at IARC and at the
National Cancer Institute’s core genotyping facility. Genotyping
was done using the 5′ nuclease assay (Taqman, Applied Biosys-
tems) or Illumina GoldenGate® Oligo Pool All (OPA) assay,
which was designed using publicly available sequencing informa-
tion. Laboratory personnel were blinded to case–control status.
Sequences of primers and probes were obtained from the SNP500
project (http://snp500cancer.nci.nih.gov/home.cfm). DNA from
cases and controls were randomized on PCR plates and dupli-
cate genotyping was performed on a randomly selected 10% of
the samples for quality control. Call rates were similar for cases
and controls, and exceeded 94% for both. All single nucleotide
polymorphisms (SNPs) had a genotyping completion rate exceed-
ing 99%. All duplicate quality control genotypes showed >99%
concordance. Detailed methods for the genotyping can be found
elsewhere (Karami et al., 2008; McKay et al., 2008).
We checked the SNPs included in this analysis against those
used in a concurrent genome-wide association study being
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Table 1 | Characteristics of the population.
Cases Controls p-Value
N % N %
SEX
Male 523 59.8 1496 72.9 <0.0001
Female 351 40.2 557 27.1
AGE
<50 150 17.2 367 17.9 0.7
50–59 270 30.9 636 31.0
60–69 280 32.0 677 33.0
70+ 174 19.9 373 19.9
COUNTRY
Romania 73 8.4 177 8.6 <0.0001
Poland 75 8.6 466 22.7
Russia 260 29.8 797 38.8
Czech Republic 466 53.3 613 29.9
BODY MASS INDEX (BMI)
<25 248 28.5 779 38.2 <0.0001
25+ 623 71.5 1261 61.8
HIGH BLOOD PRESSURE
No 483 55.3 1272 62.0 0.0008
Yes 390 44.7 780 38.0
ALCOHOL INTAKE (g/DAY, QUARTILES)
0–518 231 31.7 429 23.8 <0.0001
519–1695 183 25.1 447 24.8
1696–4229 170 23.3 462 25.6
4230+ 145 19.9 468 25.9
TOBACCO (PACK-YEARS)
None 409 46.8 729 35.5 <0.0001
1–19 192 22.0 512 24.9
20+ 273 31.2 812 39.6
p-Values by chi-square testing.
conducted by our group, which used the Illumina 317K chip.
Overall we found poor coverage of the genes of interest in this
study with SNPs included in our GWAS, with most LD r2< 0.05.
The exception was rs1056836, for which there was an r2 of 0.77
with rs162330.
STATISTICAL ANALYSIS
Each polymorphism was tested in controls to ensure adherence to
Hardy–Weinberg equilibrium (Table 2). SNPs exceeding Hardy–
Weinberg equilibrium (p< 0.01) were excluded from the present
analysis. For each SNP, we calculated odds ratios (OR) and 95%
conﬁdence intervals (CI) using unconditional logistic regression
after adjusting for potential confounders including country of resi-
dence, age (continuous), sex, blood pressure (high/low or normal),
alcohol intake (g/day, quartile based upon the distribution in con-
trols), and body mass index (<25, 25+). Analyses were conducted
with SAS (Cary, NC, USA).
Haplotypes were calculated using fastPhase software (Scheet
and Stephens, 2006). The fastPhase haplotypes were then used
as covariates in the unconditional logistic regression model. We
considered NAT1∗10 the highest risk genotype, as has been seen
elsewhere, and additionally examined the risk associated with
other genotypes (Bell et al., 1995; Cascorbi et al., 2001). Indi-
viduals homozygous for rapid NAT2 acetylator alleles (NAT2∗4,
NAT2∗11A, NAT2∗12A, NAT2∗12B, NAT2∗12C, NAT2∗13) were
classiﬁed as rapid acetylator phenotype. Those homozygous
for slow acetylator alleles were classiﬁed as slow acetylator
phenotype and heterozygous individuals (one rapid and one
slow NAT2 allele) were classiﬁed as intermediate acetylator
phenotype. We further examined the risk for speciﬁc haplo-
types. In response to another investigation (Longuemaux et al.,
1999), we examined whether any additional risk was conferred
among NAT2 slow acetylators who also had rarer variants of
CYP1A1.
We conducted an exploratory analysis of exposure to occu-
pational carcinogens among those with selected variants, and
checked our ﬁndings in a case-only analysis. Stratiﬁed analy-
ses were performed by exposure to gasoline, pesticides, and
trichloroethylene. Given that tobacco use in some eastern Euro-
pean countries continues to rise (Bosetti et al., 2005; Perlman et al.,
2007; Oh et al., 2010), we additionally examined joint effects with
tobacco use.
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Table 3 | Odds ratios (OR), 95% confidence intervals (95%CI) for the
associations of polymorphisms in NAT and renal cell cancer risk.
Case Control OR (95% CI)
N N
NAT1
Rapid 572 1341 Referent
Intermediate 253 626 1.03 (0.85, 1.26)
Slow 30 58 1.12 (0.88, 1.43)
NAT2
Rapid 54 108 Referent
Intermediate 310 731 0.76 (0.51, 1.14)
Slow 491 1172 0.82 (0.69, 1.01)
OR (95% CI) by unconditional logistic regression, controlling for age, sex, study
center, high blood pressure, body mass index, pack-years of cigarette smoking,
and alcohol intake.
RESULTS
Of the 954 eligible kidney cancer cases who provided genomic
DNA, 80 were excluded due to having histology other than renal
cell carcinoma. The 874 cases in the current analysis had clear
cell carcinoma (N = 792, 90.6%), papillary (N = 61, 7.0%), chro-
mophobe (N = 19, 2.2%), and two (<1%) cases of oncocytic
neoplasm.
The population was described in Table 1. The largest propor-
tion of participants was from the Czech Republic. Cases were
more likely to be overweight or obese and were more likely to
have high blood pressure, in comparison to controls. Controls
had greater tobacco use than cases, with the greatest person-years
of tobacco use observed in Russia and Poland (data not shown).
After elimination of three SNPs that were out of Hardy–Weinberg
equilibrium, 56 SNPs remained (Table 2). In the main effects
analysis, CYP1B1V432L was associated with RCC risk (p = 0.03).
Examining this variant, we additionally tested for heterogeneity of
results. We did observe different associations by country of res-
idence (p =< 0.0001). Results of a random effects model were
similar to the ﬁxed effects regression (OR= 1.13, 95% CI 1.01,
1.27). After adjustment for multiple comparisons via Bonferroni,
it did not remain signiﬁcant.
In haplotype analyses, we did not observe any association
between RCC and NAT1∗10 or with NAT2 slow acetylation
(Table 3). We were not able to replicate the ﬁndings of Longue-
maux et al. (1999) who observed additional risk among NAT2
slow acetylators with rarer CYP1A1 variants (OR= 1.57, 95%CI
0.96, 2.56). After stratifying by occupational exposures, we did not
observe a greater risk for RCC among NAT1∗10 or NAT2 slow
acetylators who were tobacco users or occupationally exposed to
chemical agents (data not shown), nor did we observe associations
when examining risk in the case-only analysis.
DISCUSSION
To our knowledge, this is the largest study yet conducted of
xenometabolic genes in relation to RCC. In this Central and
Eastern European population, we observed no clear associations
between RCC and genetic variation in the xenometabolic genes. It
is likely that if these variants had a true association with disease,
we would have observed differing effects between smokers and
non-smokers. Although this study’s controls had high rates of
smoking, making such a differential effect difﬁcult to observe
(Heck et al., 2010),we also did not see associations in the case-only
analysis.
To our knowledge, there have been two other studies examining
NAT2 slow acetylation andRCC.One study (N cases= 115) found
a strong association between NAT2 genotype and RCC (OR= 1.8;
Semenza et al., 2001). The other (N cases= 73) found no indepen-
dent association with slow acetylator genotype alone (OR= 1.1),
although a greater risk was seen among persons who also had cer-
tain CYP1A1 variants (Longuemaux et al., 1999).We were not able
to replicate these results.Differingﬁndings are likely due to chance.
The CYP1B1∗3 variant was common, with 47.0% of total sam-
ples heterozygous C/G and 18.2% homozygous G/G. This geno-
type is associated with an amino acid substitution from leucine
to valine, with higher catalytic activity for Val432 variants than
Leu432 variants, potentially causing a differential susceptibility
toward tobacco-related cancers. A small study in Japan reported a
50% increase in RCC among heterozygous C/G participants, and
an over twofold risk among homozygous G/G participants (Sasaki
et al., 2004). This variant has been tested in relation to several
other cancers and health conditions. The literature is inconsistent
as to whether there is a relationship between this variant and lung
cancer (Wenzlaff et al., 2005; Cote et al., 2007; Shah et al., 2008),
while no association has been seen with cancers of the ovary or
head and neck (Cecchin et al., 2004; Singh et al., 2008).
One study reported higher prevalence of NQO1 variants among
RCC patients (Schulz et al., 1997). In our population, there was a
marginally greater prevalence among cases of polymorphisms of
NQO1 codon 187 (p = 0.07), while the distribution of all other
NQO1 SNPs did not differ between cases and controls.
If genetic susceptibility to renal cancer is mediated through
metabolic gene polymorphisms, it is possible that combinations of
genotypesmay be amoremeaningful predictor of disease risk than
examining single loci genotype, and this study lacked power to do
detailed analyses. A strength of the study is the expected genetic
homogeneity of the eastern European population, lowering the
likelihood of bias from population stratiﬁcation (Wacholder et al.,
2000). Nonetheless, we did observe heterogeneity in the results.
Hospital-based controls in our study could potentially cause selec-
tion bias if speciﬁc genetic variants were related to hospitaliza-
tion. However, controls with a variety of medical conditions were
recruited into the study, lessening the likelihood of such a bias.
In conclusion, no clear associations were observed between
RCC and several polymorphisms related to xenobiotic metabo-
lism.
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